Home › Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
 

Keywords :   


Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

2014-10-22 15:11:12| Biotech - Topix.net

Ipsen and Lexicon Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan.

Tags: enter agreement licensing lexicon

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »